Literature DB >> 17196909

Cognitive function impairment in patients with neuropathic pain under standard conditions of care.

Mónica Povedano1, Jordi Gascón, Rafael Gálvez, Manuel Ruiz, Javier Rejas.   

Abstract

The objective of this study is to analyze the prevalence to cognitive function impairment (CI) in a pragmatic cohort of subjects with different types of neuropathic pain under standard conditions of care by means of a cross-sectional baseline analysis of a sample of patients with NeP enrolled in a pragmatic, prospective, multicenter study evaluating the effectiveness of gabapentin. A total of 1519 patients (58.8% women), aged > or =18 years (mean [SD]=56.0 [13.7]), with neuropathic or mixed neuropathic and nociceptive pain for a mean (SD) of 1.1 (2.8) years were enrolled in the study. Pain was assessed with the short form of the McGill Pain Questionnaire, and cognitive function was measured with the Mini-Mental State Examination (MMSE). A score < or =24 on the MMSE was considered as CI. Multivariate logistic regression models were used to estimate CI prevalence. CI prevalence was substantially higher in patients with NeP than that reported in the general Spanish population, and significantly higher than in patients with mixed neuropathic and nociceptive pain: 11.4% (8.5%-14.3%) vs. 6.4% (4.6%-8.7%), P=0.006 (adjusted odds ratio=1.88 [1.21-2.91]). Prevalence significantly increased with age, up to 32.2% (20.6%-45.6%) in those with NeP, and to 28.2% (15.0%-44.9%) in those with mixed syndromes, for the age group > or =75 years, P<0.001 within age groups. Symptoms of anxiety and obesity, and to a lesser extent, symptoms of depression, were also factors associated with a higher prevalence rate of CI. This analysis showed that, after adjusting for confounding factors, the prevalence of CI was substantially higher in patients with NeP than those with mixed pain and the reference general population. Age, anxiety, depression, and obesity were factors found to be significantly associated with CI.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17196909     DOI: 10.1016/j.jpainsymman.2006.07.012

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  23 in total

1.  Sex-Specific Disruption of Distinct mPFC Inhibitory Neurons in Spared-Nerve Injury Model of Neuropathic Pain.

Authors:  Andrea F Jones; Patrick L Sheets
Journal:  Cell Rep       Date:  2020-06-09       Impact factor: 9.423

2.  The Relationship Between Chronic Pain and Neurocognitive Function: A Systematic Review.

Authors:  Diana M Higgins; Aaron M Martin; Dewleen G Baker; Jennifer J Vasterling; Victoria Risbrough
Journal:  Clin J Pain       Date:  2018-03       Impact factor: 3.442

3.  Post-conditioning experience with acute or chronic inflammatory pain reduces contextual fear conditioning in the rat.

Authors:  Ian N Johnston; Steven F Maier; Jerry W Rudy; Linda R Watkins
Journal:  Behav Brain Res       Date:  2011-09-06       Impact factor: 3.332

4.  The Temporal Relationship between Pain Intensity and Pain Interference and Incident Dementia.

Authors:  Ali Ezzati; Cuiling Wang; Mindy J Katz; Carol A Derby; Andrea R Zammit; Molly E Zimmerman; Jelena M Pavlovic; Martin J Sliwinski; Richard B Lipton
Journal:  Curr Alzheimer Res       Date:  2019       Impact factor: 3.498

5.  Reversal of peripheral nerve injury-induced neuropathic pain and cognitive dysfunction via genetic and tomivosertib targeting of MNK.

Authors:  Stephanie Shiers; Juliet Mwirigi; Grishma Pradhan; Moeno Kume; Bryan Black; Paulino Barragan-Iglesias; Jamie K Moy; Gregory Dussor; Joseph J Pancrazio; Sven Kroener; Theodore J Price
Journal:  Neuropsychopharmacology       Date:  2019-10-07       Impact factor: 7.853

6.  Pain, neuropathic symptoms, and physical and mental well-being in persons with cancer.

Authors:  Cindy S Tofthagen; Susan C McMillan
Journal:  Cancer Nurs       Date:  2010 Nov-Dec       Impact factor: 2.592

7.  Neuropathic Pain Creates an Enduring Prefrontal Cortex Dysfunction Corrected by the Type II Diabetic Drug Metformin But Not by Gabapentin.

Authors:  Stephanie Shiers; Grishma Pradhan; Juliet Mwirigi; Galo Mejia; Ayesha Ahmad; Sven Kroener; Theodore Price
Journal:  J Neurosci       Date:  2018-07-20       Impact factor: 6.167

8.  Cognitive impairment in patients with fibromyalgia syndrome as assessed by the mini-mental state examination.

Authors:  Jose Rodríguez-Andreu; Rosario Ibáñez-Bosch; Amparo Portero-Vázquez; Xavier Masramon; Javier Rejas; Rafael Gálvez
Journal:  BMC Musculoskelet Disord       Date:  2009-12-21       Impact factor: 2.362

9.  Prevalence and characterization of neuropathic pain in a primary-care setting in Spain: a cross-sectional, multicentre, observational study.

Authors:  Concepción Pérez; María Teresa Saldaña; Ana Navarro; Inma Vilardaga; Javier Rejas
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

Review 10.  Cognition and Pain: A Review.

Authors:  Tanvi Khera; Valluvan Rangasamy
Journal:  Front Psychol       Date:  2021-05-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.